|Videos|December 22, 2019
Treating HER2-Positive Metastatic Breast Cancer: DESTINY-Breast02 and DESTINY-Breast03
Author(s)Sponsored Content
The role of antibody drug conjugate DS-8201a (trastuzumab deruxtecan) in the treatment of HER2-positive metastatic breast cancer and an overview of the DESTINY-Breast02 and DESTINY-Breast03 trials.
Advertisement
The role of antibody drug conjugate DS-8201a (trastuzumab deruxtecan) in the treatment of HER2-positive metastatic breast cancer and an overview of the DESTINY-Breast02 and DESTINY-Breast03 trials.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CURE
1
Acupuncture Improves Cognitive Function in Breast Cancer Survivors
2
From Stage 4 to Survivor: Dan’s Pancreatic Cancer Journey
3
Light the Night and Survivorship: The Importance of Remembrance
4
FDA Approves Akeega Combo in BRCA2+ Metastatic Prostate Cancer
5
